See every side of every news story
Published loading...Updated

First release RETNET data show no difference in progression-free survival between TAE and TACE for neuroendocrine liver tumours - Interventional News

Summary by Interventional News
Michael Soulen presents at SIO 2025 New data from a prospective, multicentre randomised controlled trial show similar hepatic progression-free survival (hPFS) using bland transarterial embolization (TAE) or transarterial chemoembolization (TACE) when treating neuroendocrine tumour metastases in the liver. Michael Soulen (University of Pennsylvania, Philadelphia, USA) presented these findings at the Society of Interventional Oncology (SIO) annual…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Interventional News broke the news in on Sunday, February 2, 2025.
Sources are mostly out of (0)